IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico August 2, 2023 Read More »
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference July 18, 2023 Read More »
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer’s Research July 7, 2023 Read More »
IGC Pharma Announces a $3 Million Private Placement of its Common Stock – Jul 6’23 July 6, 2023 Read More »